Alzheimer's Disease

Specialties

Alzheimer's Disease

Until recently, there has been no amyloid-targeting treatment available for Alzheimer's disease. We imagine a future where providers have the tools needed to identify, diagnose, select the right treatment, and monitor and visualize treatment response. A future where a strong provider network collaborates with patients and their families to identify signs of Alzheimer’s – even before symptoms begin.

We are here to instill hope in the face of Alzheimer's disease and to make this vision a reality.

Facts and Figures¹

6.7M

Estimated number of Americans are living with Alzheimer’s Disease, which will likely grow to 12.7 M by 2050

7th

leading cause of death in the United States

18B

estimated hours of unpaid care provided by caregivers of people with Alzheimer’s Disease or other dementias

$345B

Projected in annual cost in the US driven by incurable, yet long-care timeline

Solutions providing hope

Our technology brings hope to those with Alzheimer’s disease, providing solutions along the patient's journey.

Disease and treatment discovery

Researchers around the globe have advanced the vision of a future without Alzheimer's disease, focused on diagnosis, disease progression, treatment, and prevention. To make these advancements, researchers need access to cutting-edge tools for both disease and treatment discovery.

Discovery

Researchers continue to study how Alzheimer’s Disease changes the brain in the hope of identifying new treatments.

Tracer production is critical in PET imaging, with each tracer produced offering a potential step towards treatment.

Cyclotrons

Isotope (¹⁸F) tracer production providing a large supply or consistent, reliable, and cost-effective tracers.

Learn more

PET Radiochemistry systems

With a unique, integrated cassette-based design and GMP-quality components, FASTlab 2 New Edition enables regulatory reliability & compliance in small-scale tracer production.

Learn more

Confident diagnosis

Without a single test for Alzheimer’s Disease, diagnosis relies on a combination of several imaging evaluations as well as neurological exams, cognitive and functional assessments, and medical history. With treatments now available, a quick and confident diagnosis is critical in giving time back to patients and caregivers.

Diagnosis

Brain imaging (MRI, PET/MR, PET/CT) is a critical component of a confident Alzheimer’s diagnosis.

Brain imaging

Visualization of brain amyloid

Structural imaging by MR is primarily used to rule out other causes of Alzheimer’s symptoms

Magnetic Resonance Imaging (MRI) Solutions

Offering efficient workflow and productivity solutions for routine scanning, our MRI scanners bring innovation for advanced clinical procedures to deliver patient satisfaction

Learn more

SIGNA™ PET/MR AIR™ scanner¹

The industry’s most sensitive Time-of-Flight (ToF) PET detector and our most capable MR scanner deliver clarity and patient comfort with every scan

Visualization of brain amyloid is critical to identifying patients with Alzheimer's disease.

OmniLegend

Omni Legend provides ultra-high sensitivity while delivering dose and scan time reduction, outstanding image quality, and quantitative accuracy.

Learn more

SIGNA™ PET/MR AIR™

The industry’s most sensitive Time-of-Flight (ToF) PET detector and our most capable MR scanner deliver clarity and patient comfort with every scan

Empowered treatment

With the introduction of amyloid-targeting treatments, disease prognosis is changing. Clinical use of these therapies require imaging to aid in patient selection, detect adverse reactions, and monitor the drug’s effectiveness & disease progression. Our innovative solutions ensure consistent, fast & high-quality MR and PET/MR scans with tools and resources for scan interpretation & quantification.

Treatment

Monitoring amyloid-related imaging abnormality (ARIA) with MR and PET/MR is critical in the course of anti-amyloid AD therapy.

Improved quality and shorter acquisition time

Scan reproducibility

Reducing scan time without impacting image quality can help your practice keep pace with a growing AD population

AIR Recon DL

A deep-learning based reconstruction for improving SNR and image sharpness, while enabling shorter scan times

Learn more

HyperSense

Delivers a compressed-sensing boost to image acceleration for faster and higher-resolution acquisitions.

Real-time applications provide motion-correction and distortion artifact reduction during the scan

PROGRES

Reducing unwanted distortion artifacts in diffusion-weighted and diffusion-tensor imaging in challenging anatomical regions

PROMO

Real-time prospective motion correction technique with minimal scan time penalty and without the need for external cameras or fiducial markers

The industry’s most sensitive Time-of-Flight (ToF) PET detector and our most capable MR scanner offer clarity and patient comfort with every scan

MotionFree Brain² for SIGNA™ PET/MR

Data-driven, retrospective motion correction technology requiring no external hardware and having no impact on the clinical routine

AD patients undergo repeat monitoring to measure disease progression and/or therapy effectiveness

AIR x™

A deep-Learning-based workflow tool that automatically identifies anatomical landmarks and prescribes slices reproducibly, for more consistent longitudinal scanning

Learn more

Disclaimers

SIGNA PET/MR AIR is a premium configuration of SIGNA PET/MR. Not CE marked. Not available in all regions.
Not CE marked. Not available in all regions.

References

Alzheimer’s Association. (2023). 2023 Alzheimer’s Disease Facts and Figures

Have a question about our products? We would love to hear from you.

Let’s talk

Thank you!

We received your request for assistance.

A GE Healthcare specialist will be reaching out shortly.

Something went wrong

We will check and get back.

Try Again

JB03032UK March 2024